Business, energy, technology, markets and global industry news from Business News Today

Narcolepsy Type 1

PharmaDeviceNews Narcolepsy Type 1
Takeda’s ORZEYFUL FDA approval introduces the first orexin receptor 2 agonist for adults with narcolepsy type 1, targeting the orexin signalling deficiency underlying the disorder. Representative image.
Pharma & Biotech

How Takeda’s ORZEYFUL could change treatment of narcolepsy type 1

Takeda Pharmaceutical Company Limited has secured United States Food and Drug Administration approval for ORZEYFUL, or oveporexton, the first oral orexin receptor 2 agonist authorised to treat narcolepsy type 1 as a complete disorder in adults. The approval introduces a new treatment mechanism, but the medicine will not become available until the Drug Enforcement Administration

Read More
Representative image: Alkermes’ alixorexton narcolepsy type 2 study highlights the potential of orexin receptor therapy to improve daytime wakefulness as Phase 3 testing examines dosing, safety and broader clinical benefit.
Pharma & Biotech

Alkermes’ alixorexton improves narcolepsy type 2 symptoms as Phase 3 risk comes into focus

Discover how Alkermes’ alixorexton could reshape narcolepsy type 2 treatment as Phase 3 tests its efficacy, dosing and long-term safety.

Read More
Representative image showing a sleep medicine consultation as Takeda’s oveporexton data highlight a potential shift in narcolepsy type 1 care.
Pharma & Biotech

Takeda’s narcolepsy data reveal why orexin agonists are becoming a neuroscience priority

Find out how Takeda’s oveporexton data could reshape narcolepsy type 1 care as approval, safety and access questions loom.

Read More